News | Radiation Therapy | September 23, 2016

ASTRO, ASCO and SSO Update Guideline on Post-Mastectomy Radiotherapy

Update provides evidence-based recommendations for the use of PMRT, considering tumor size, positive lymph nodes and risk/benefit ratio

ASTRO, ASCO, SSO, guideline update, post-mastectomy radiotherapy, PMRT, radiation therapy

September 23, 2016 — Three leading national cancer organizations issued a joint clinical practice guideline update for physicians treating women with breast cancer who have undergone a mastectomy. The update provides additional considerations for physicians to determine which patients might benefit from post-mastectomy radiotherapy (PMRT)

“We still don’t have a single, validated formula that can determine who needs PMRT, but we hope that the research evidence summarized in this guideline update will help doctors and patients make more informed decisions,” said Stephen B. Edge, M.D., co-chair of the Expert Panel that developed the guideline update. “We also hope that this publication will spur more research into patient and tumor characteristics that predict risk of recurrence after mastectomy.”

The American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO) together published the new guideline update in their respective journals, the Journal of Clinical OncologyPractical Radiation Oncology and Annals of Surgical Oncology.

“In an era of personalized medicine, we want to be sure that we offer the right care to the right patients. Thanks to advances in systemic therapy, fewer women need radiation therapy after a mastectomy,” said Abram Recht, M.D., co-chair of the Expert Panel that developed the guideline update. “This means we can be more selective when recommending this treatment to our patients.” 

The guideline update states that there is strong evidence showing that PMRT reduces the risk of breast cancer recurrence. It provides evidence-based recommendations for the use of post-mastectomy radiotherapy in: patients with T1-2 tumors (tumors smaller than 5 cm) and one to three positive lymph nodes; patients undergoing neoadjuvant systemic therapy (NAST); and patients with T1-2 tumors and a positive sentinel node biopsy. The Expert Panel also addressed technical aspects of radiotherapy, such as the optimal extent of regional nodal irradiation (RNI).

“For many women, PMRT reduces the risk of local and regional failure, but physicians must weigh this benefit with the considerable side effects associated with this treatment,” said Bruce G. Haffty, M.D., immediate past chair of ASTRO’s Board of Directors. “This cooperative guideline underscores the complexity inherent in decisions related to PMRT, as well as the importance of clinical judgment in treatment planning.”

To develop this guideline update, an Expert Panel reviewed relevant literature published between January 2001 and July 2015. This included a meta-analysis of 22 clinical trials published in 2014, which provides evidence that PMRT is highly effective at preventing local breast cancer recurrence.

Key recommendations of the guideline update are as follows:

  • Decision to use PMRT should involve providers from all treating disciplines as well as the patient. Doctors and patients should discuss risks and benefits to determine the best treatment approach for the patient;
  • For women with T1-2 breast cancer and one to three positive lymph nodes, PMRT reduces the risk of recurrence and breast cancer death. However, for some patients with a low risk of recurrence, the potential complications of PMRT may outweigh the benefit;
  • When making decisions on recommending PMRT, doctors should consider patient and tumor characteristics that may diminish the benefit of PMRT or increase the risk of complications;
  • Patients with T1-2 tumors with a positive sentinel node biopsy who elect to omit axillary lymph node dissection should receive PMRT only if there is already sufficient information to justify its use without needing to know that additional axillary nodes are involved;
  • Patients with axillary nodal involvement that persists following neoadjuvant systemic therapy should receive PMRT; and
  • Radiation should generally be given to both the internal mammary nodes and the supraclavicular-axillary apical nodes in addition to the chest wall or reconstructed breast when PMRT is used for patients with positive axillary lymph nodes. 

“This guideline highlights the need to individualize therapy as well as identifies areas where more research is needed,” said Monica Morrow, M.D., FACS, the SSO representative on the Expert Panel that developed the guideline update. “It emphasizes that we are moving beyond a simplistic one size fits all approach to more tailored therapy which will improve benefits for patients.”

For more information: www.annsurgoncol.org, www.practicalradonc.org, www.jco.ascopubs.org

Related Content

Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...
Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones
News | Radiation Therapy | July 05, 2019
Aktina Medical announced that Elekta Instrument AB, based in Sweden, will offer and distribute the Aktina line of...